Home / Regulatory
Peptide regulation changed three times in 2026, and almost every account of it you will read online is wrong in the same specific way. This page explains what happened, what it means, and what has not happened yet.
Free, no obligation
Every inquiry gets a real answer from a person. If what you're asking about isn't supported by evidence, we'll say so.
The single most misread fact: twelve peptides were removed from Category 2 in April 2026. Removal from the restricted list is not the same as being cleared for use. With one exception, none of those substances were moved to Category 1, and none appear on FDA's current nomination lists. They occupy a gap. Neither prohibited nor permitted. Any seller describing them as newly legal is misrepresenting the April action.
FDA placed a large group of peptides into Category 2 of the 503A bulk drug substances review, substances raising significant safety risks. Compounding pharmacies could not legally use them. This is the action that pushed most peptide activity into the grey market.
FDA published seven warning letters against online sellers marketing GLP-1 copycats as research chemicals. The letters established the agency's operating theory plainly: intended use is inferred from context. Product claims, accompanying items, how a thing is sold. And a disclaimer does not override it.
Twelve substances were removed from Category 2 after their nominations were withdrawn. Critically, with the exception of GHK-Cu, none were moved to Category 1, and they do not appear on FDA's nomination lists. Removal from the restricted list did not make anything compoundable. This single point is the most widely misrepresented fact in the market.
The Pharmacy Compounding Advisory Committee met over two days and voted on seven peptides. Six received favourable recommendations. One was rejected. The committee sided with demand over the objections of FDA's own scientific staff, who had recommended against all seven on evidentiary grounds.
FDA is not bound by the committee. To change anything, the agency must publish a proposed rule, open a public comment period, review comments, and issue a final rule. That process commonly runs up to a year. Until a final rule appears in the Federal Register, nothing has legally changed.
A further advisory meeting is scheduled before the end of February 2027 to consider LL-37, GHK-Cu, dihexa, Melanotan II and PEG-MGF. Nothing about these is decided.
Seven peptides went before the Pharmacy Compounding Advisory Committee. These recommendations are non-binding. FDA has issued no rule, and until it does, none of these substances may be compounded.
| Status | What it means |
|---|---|
| Category 1 | Eligible for compounding Substances FDA has reviewed and permitted for use in 503A compounding. A pharmacy may use these. |
| Category 2 | Significant safety risk Substances FDA has determined raise significant safety risks. Not permitted. |
| Category 3 | Insufficient information Nominated substances where the information submitted was inadequate to evaluate. Not permitted while under review. |
| Not listed | No status at all Substances on none of the lists. This is where most peptides removed from Category 2 in April 2026 now sit. Absence from Category 2 is not permission, a substance must be affirmatively on Category 1 to be compounded. |
Peptide regulation involves at least four separate questions that are routinely collapsed into one. Is the compound an approved drug? Is it permitted for compounding by a 503A pharmacy? Is it a legal dietary supplement? Is it a legal cosmetic ingredient? A compound can be a clear yes on one and a clear no on the others. Marketing tends to find whichever answer is most favourable and present it as the whole picture.
An FDA-approved drug has been through clinical trials and agency review for a specific indication. Semaglutide, tirzepatide, tesamorelin, PT-141, hCG and oxytocin are approved. Most compounds discussed on this site are not. Approval in another country does not create a United States pathway, regulators reach different conclusions on the same data.
Compounding pharmacies operate under sections 503A and 503B of the Food, Drug and Cosmetic Act. A 503A pharmacy compounds for an identified patient with a prescription. A 503B outsourcing facility manufactures at larger scale under cGMP. Either may only use bulk substances that are components of approved drugs, appear in an applicable monograph, or sit on FDA's 503A Bulks List. The advisory committee process governs what reaches that list.
Under DSHEA, dietary supplements must be ingested and must be dietary ingredients, vitamins, minerals, herbs, amino acids, or dietary substances with a history of use in food. Collagen peptides qualify because they derive from food sources. A synthetic peptide like BPC-157 does not: it is not an amino acid in the relevant sense, it has no history of food use, and the ingestion requirement excludes anything injectable outright. Oral peptide products marketed as supplements are generally unapproved drugs.
Topical products are regulated as cosmetics, with no pre-market approval, provided the claims stay within cosmetic territory: appearance, moisturising, reducing the look of lines. The moment a product claims to treat, cure, or alter the structure or function of skin, it becomes a drug claim and the product becomes an unapproved drug. This is why cosmetic peptide labelling is worded so carefully.
The pivotal concept in every enforcement action this year. Under section 201(g)(1), a product becomes a drug when it is intended to affect the structure or function of the body. Intent is not what a seller declares. It is inferred from the whole context: the claims on the page, what else is in the cart, storage and preparation instructions, and how the product is marketed. In the 2026 letters, research-use disclaimers appearing alongside dosing information and injection supplies were treated as evidence of knowledge rather than as a defence.
This is a plain-language summary of publicly available regulatory information, current to 19 August 2026. It is not legal advice, and Bloodline is not a law firm. Regulatory status changes, sometimes quickly. Anyone making business or clinical decisions on the basis of any of this should verify current status directly against the Federal Register and consult a qualified attorney.
Understanding the landscape is one thing. Whether any of it fits your situation is a question worth asking a person.
See consultations